TY - JOUR
T1 - Protocol for the COG-UK hospital-onset COVID-19 infection (HOCI) multicentre interventional clinical study
T2 - evaluating the efficacy of rapid genome sequencing of SARS-CoV-2 in limiting the spread of COVID-19 in UK NHS hospitals
AU - The COVID-19 Genomics UK (COG-UK) Consortium
AU - Blackstone, James
AU - Stirrup, Oliver
AU - Mapp, Fiona
AU - Panca, Monica
AU - Copas, Andrew
AU - Flowers, Paul
AU - Hockey, Leanne
AU - Price, James
AU - Partridge, David
AU - Peters, Christine
AU - De Silva, Thushan
AU - Nebbia, Gaia
AU - Snell, Luke B.
AU - McComish, Rachel
AU - Breuer, Judith
AU - Bashton, Matthew
AU - McCann, Clare
AU - Nelson, Andrew
AU - Smith, Darren
AU - Young, Gregory R.
N1 - Funding information: The COG-UK HOCI study is funded by the COG-UK Consortium, which is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute (UKRI MRC Grant number MC PC 19027).
Matthew Bashton, Andrew Nelson, Darren Smith, Greg Young and Clare McCann are members of the COVID-19 Genomics UK consortium.
PY - 2022/4/19
Y1 - 2022/4/19
N2 - Objectives: Nosocomial transmission of SARS-CoV-2 has been a significant cause of mortality in National Health Service (NHS) hospitals during the COVID-19 pandemic. The COG-UK Consortium Hospital-Onset COVID-19 Infections (COG-UK HOCI) study aims to evaluate whether the use of rapid whole-genome sequencing of SARS-CoV-2, supported by a novel probabilistic reporting methodology, can inform infection prevention and control (IPC) practice within NHS hospital settings. Design: Multicentre, prospective, interventional, superiority study. Setting: 14 participating NHS hospitals over winter-spring 2020/2021 in the UK. Participants: Eligible patients must be admitted to hospital with first-confirmed SARS-CoV-2 PCR-positive test result >48 hour from time of admission, where COVID-19 diagnosis not suspected on admission. The projected sample size is 2380 patients. Intervention: The intervention is the return of a sequence report, within 48 hours in one phase (rapid local lab processing) and within 5-10 days in a second phase (mimicking central lab), comparing the viral genome from an eligible study participant with others within and outside the hospital site. Primary and secondary outcome measures The primary outcomes are incidence of Public Health England (PHE)/IPC-defined SARS-CoV-2 hospital-acquired infection during the baseline and two interventional phases, and proportion of hospital-onset cases with genomic evidence of transmission linkage following implementation of the intervention where such linkage was not suspected by initial IPC investigation. Secondary outcomes include incidence of hospital outbreaks, with and without sequencing data; actual and desirable changes to IPC actions; periods of healthcare worker (HCW) absence. Health economic analysis will be conducted to determine cost benefit of the intervention. A process evaluation using qualitative interviews with HCWs will be conducted alongside the study.
AB - Objectives: Nosocomial transmission of SARS-CoV-2 has been a significant cause of mortality in National Health Service (NHS) hospitals during the COVID-19 pandemic. The COG-UK Consortium Hospital-Onset COVID-19 Infections (COG-UK HOCI) study aims to evaluate whether the use of rapid whole-genome sequencing of SARS-CoV-2, supported by a novel probabilistic reporting methodology, can inform infection prevention and control (IPC) practice within NHS hospital settings. Design: Multicentre, prospective, interventional, superiority study. Setting: 14 participating NHS hospitals over winter-spring 2020/2021 in the UK. Participants: Eligible patients must be admitted to hospital with first-confirmed SARS-CoV-2 PCR-positive test result >48 hour from time of admission, where COVID-19 diagnosis not suspected on admission. The projected sample size is 2380 patients. Intervention: The intervention is the return of a sequence report, within 48 hours in one phase (rapid local lab processing) and within 5-10 days in a second phase (mimicking central lab), comparing the viral genome from an eligible study participant with others within and outside the hospital site. Primary and secondary outcome measures The primary outcomes are incidence of Public Health England (PHE)/IPC-defined SARS-CoV-2 hospital-acquired infection during the baseline and two interventional phases, and proportion of hospital-onset cases with genomic evidence of transmission linkage following implementation of the intervention where such linkage was not suspected by initial IPC investigation. Secondary outcomes include incidence of hospital outbreaks, with and without sequencing data; actual and desirable changes to IPC actions; periods of healthcare worker (HCW) absence. Health economic analysis will be conducted to determine cost benefit of the intervention. A process evaluation using qualitative interviews with HCWs will be conducted alongside the study.
KW - COVID-19
KW - epidemiology
KW - infection control
KW - molecular biology
UR - http://www.scopus.com/inward/record.url?scp=85128798654&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-052514
DO - 10.1136/bmjopen-2021-052514
M3 - Article
C2 - 35440446
AN - SCOPUS:85128798654
SN - 2044-6055
VL - 12
JO - BMJ Open
JF - BMJ Open
IS - 4
M1 - e052514
ER -